Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Though they have taken the world by storm, GLP-1 drugs like semaglutide — sold as Ozempic ... struggled to package GLP-1 agonists and other peptide-based drugs into pill form because peptides ...

Obesity medicine experts clear up common misunderstandings and misinformation about these powerful weight loss medications ...

A team of scientists led by the A*STAR Genome Institute of Singapore (A*STAR GIS) have released one of the world's largest ...